Important disclaimer: No settlements have been reached in MDL 3163 as of March 2026. This page is for educational purposes only and does not predict or guarantee any case outcome. Case values vary significantly based on individual facts. Speak with a licensed attorney to evaluate your specific situation.

Why NAION Cases May Be High-Value

Non-Arteritic Anterior Ischemic Optic Neuropathy causes permanent, life-altering harm. Compared to many pharmaceutical injury claims, NAION cases have several features that typically drive higher settlement values:

  • Permanency: Vision lost to NAION is generally not recoverable — damages are lifelong
  • Objective evidence: NAION is objectively diagnosable via visual field testing and OCT imaging — no subjective "soft" injury
  • Jury sympathy: Blindness and vision loss generate strong jury sympathy — comparable to hearing loss cases but potentially more impactful
  • No Daubert hurdle (currently): Unlike some mass torts, the Harvard study provides strong peer-reviewed scientific support for causation
  • Manufacturer culpability: Novo Nordisk's failure to update US labels despite the Harvard study may be seen as egregious conduct by juries

Key Factors That Affect Case Value

1. Severity of Vision Loss

This is the single most important factor. Cases are typically tiered by injury severity:

Tier 1 — Most Severe

Complete or near-complete vision loss in both eyes (bilateral NAION). Total functional blindness. Highest expected case values.

Tier 2 — Severe

Complete vision loss in one eye, or severe loss in both eyes. Cannot drive, significant functional impairment. High expected case values.

Tier 3 — Moderate

Partial vision loss in one eye. Moderate functional impairment. Can still drive/work with adaptations. Moderate expected case values.

Tier 4 — Mild

Mild visual field defect, mostly asymptomatic in daily life. Documented NAION but limited functional impact. Lower expected case values but still potentially compensable.

2. Impact on Employment

Lost earning capacity is a major component of damages in vision loss cases:

  • Professions requiring sharp vision (surgeons, pilots, drivers, chefs, craftspeople) may see total career termination
  • Office workers and professionals may face significant productivity impairment
  • Retired individuals have lower lost earnings but still carry significant non-economic damages

3. Age at Injury

Younger plaintiffs with more working years ahead typically receive higher economic damages. However, NAION affects all ages, and a 65-year-old with bilateral blindness still has significant non-economic damages (pain and suffering, loss of enjoyment of life).

4. Documentation Quality

Cases with strong documentation are worth more in settlement negotiations:

  • Clear temporal connection between GLP-1 use and NAION onset
  • Diagnosis confirmed by ophthalmologist with visual field testing and OCT
  • Complete prescription history showing dates, doses, and duration
  • Medical records documenting functional impairment

5. Prior NAION History

If you had any NAION in the affected eye before starting the GLP-1 drug, defendants will argue the second event was unrelated. Clean prior eye history strengthens your case.

6. Contributory Risk Factors

NAION has independent risk factors (diabetes, hypertension, sleep apnea, small optic disc). Defendants will argue these pre-existing factors caused or contributed to NAION. Cases with otherwise healthy optic nerve histories and minimal traditional risk factors are stronger.

7. State of Filing

Damages rules vary by state. Some states cap pain-and-suffering damages; others do not. Punitive damages availability also varies. Your state's law affects the ceiling on potential recovery.

Comparable Mass Tort Settlement Context

For context, here are some pharmaceutical mass tort settlements involving permanent injuries:

  • Vioxx (Merck): $4.85 billion settlement — cardiovascular injuries
  • Risperdal (J&J): $2.2 billion settlement — gynecomastia, brain injuries
  • Talcum powder (J&J): $8.9 billion proposed settlement — ovarian cancer
  • Camp Lejeune: Ongoing — billions projected for veterans' injuries

These figures are for reference only. GLP-1 NAION cases involve different injuries, defendants, and legal theories. No prediction can be made about MDL 3163 settlement amounts at this early stage.

Estimate Your Potential Case Factors

Check the factors that apply to you:

This tool is for educational purposes only and does not predict actual settlement values. Consult a licensed attorney for case-specific evaluation.